Abstracts 55 was £4,142 compared to £3,762 on PE. Overall tumour response was 40.6% and 21.9% respectively and progression-free life years 0.575 and 0.358. Thus, the incremental cost-per-tumour-response of GC was £2,032 and the incremental cost-per-progression-free-life-year £1,751. In the final setting, the cost of GC was £5,084 and of MVP £4,004. Overall tumour response was 54.0% and 36.7% and one year survival 36% and 17% respectively. The incremental cost-per-tumour-response of GC was £6,240 and the incremental cost-per-survivor-at-one-year was £5,681. In extreme changes to underlying variables the above ratios vary from dominance to a maximum of £14,000. CONCLUSIONS: These results demonstrate that Gemzar/cisplatin represents a relatively cost-effective treatment for NSCLC with ratios comparable of below those of therapies currently in use within the NHS.
OBJECTIVES:
To identify the association between compliance and the direct costs of care for two different clinical patient cohorts. METHODS: Using administrative claims data from Medstat MarketScan (tm) we assessed the association between prescription drug compliance and direct costs of care for two patient groups: a cohort of non-Medicare patients diagnosed as diabetics (N ϭ 9960) and second cohort of non-Medicare patients diagnosed with congestive heart failure (CHF)(N ϭ 935). Since patients who are more compliant tend to be older and have a greater number of comorbidities, and our goal was to isolate the association between compliance and medical care costs, we statistically controlled for differences in potential confounding variables using OLS regression. Covariates included age, gender, comorbidity indices (Chronic Disease Score and Charlson-Deyo), and ICD-9-based severity of illness indicators. Compliance was defined by calculating % days supply over a period of one year. Compliance was then converted to 7 ordinal categories in the regression model in order to identify dose-response associations or threshold/inflection points. RESULTS: Among diabetics, those who did not use any prescription medication showed the lowest total costs of care. However, among those patients who needed prescription medication to manage their illness, increased prescription drug costs among the most compliant are more than offset by decreases in medical care costs, for an estimated return on investment (ROI) of more than two-fold. A similar, but stronger, pattern was found among patients with CHF where the estimated ROI was three-fold or greater. CONCLUSIONS: For some medical conditions, the additional costs associated with increased compliance may be offset by lower medical costs, resulting in an ROI greater than one. We present an example of using meta-analysis for an indirect comparison of 2 drugs, with the results subsequently validated in a direct comparison trial. METH-ODS: The drugs for comparison were abciximab and tirofiban, both GPIIb/IIIa inhibitors used in patients with acute coronary syndromes undergoing percutaneous coronary interventions (PCI). A class effect has been assumed for these agents, although they differ in molecular structure and duration of action. We identified all placebo-controlled trials of each drug in PCI patients, and meta-analysed the odds ratios (OR) for death or MI (D/MI) at 30 days for each set of studies. These ORs were then compared using a general linear model. RESULTS: For D/MI at 30 days, the results of the meta-analysis of the 6 abciximab studies [OR ϭ 0.52 (0.43, 0.63)] appeared superior to the results of the 3 tirofiban studies [OR ϭ 0.73 (0.55, 0.96)], although the differences did not reach significance. In the model, a non-significant (p ϭ 0.10) abciximab advantage was observed. The ratio of the ORs of tirofiban/placebo and abciximab/placebo meta-analyses was 1.4, suggesting a higher risk of D/MI at 30 days for tirofiban relative to abciximab. After completion of these analyses, the results of a randomized comparison trial of tirofiban vs. abciximab in PCI patients were announced (for D/MI at 30days OR ϭ 1.26, p ϭ 0.04). The results demonstrated an advantage for abciximab, in keeping with our meta-analysis result. The magnitude of the efficacy difference was similar to that we had predicted. CONCLUSIONS: This is the first time an indirect comparison of drugs using meta-analytic techniques has been validated with a contemporaneous RCT. This method should be used to predict results of direct comparisons of drugs anytime such a trial is contemplated. 
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DO SHORT-ACTING OPIATES IN OFF-PUMP BYPASS SURGERY REDUCE LENGTH OF STAY OR TOTAL HOSPITAL COSTS?
OBJECTIVES:
The cost of remifentanil, a short-acting opiate, is approximately 10 times higher than fentanyl, a longer-acting opiate. Short-acting opiates, however, have the potential to reduce time to extubation (TTE) and may, therefore, decrease length of stay (LOS) and hospital costs. Remifentanil was added to our institution's formulary for use during off-pump bypass surgery. The objective of this analysis was to compare TTE, LOS and total hospital costs between patients who received remifentanil and fentanyl during off-pump bypass surgery. METHODS: The study was prospective and observational in design. Consecutive patients who underwent off-pump cardiac bypass surgery and received either remifentanil or fentanyl from September 1998 to August 1999 were included. Patient charges were converted to costs using cost-to-charge ratios. The percent of patients extubated in the operating room (OR), LOS and hospital costs were compared between the groups. RESULTS: Baseline demographics, including age, female patients, co-morbidities and intraoperative variables were similar between the remifentanil (n ϭ 39) and fentanyl (n ϭ 20) groups. Patients given remifentanil during surgery were significantly more likely to be extubated in the OR than patients given fentanyl (64% vs. 15%; p Ͻ 0.001). The mean LOS was similar in both groups (7.3 Ϯ 3.1d vs. 8.3 Ϯ 2.7d; p ϭ 0.27). Patients who received remifentanil incurred lower ward ($3,973 Ϯ 1,719 vs. $4,808 Ϯ 1,794; p ϭ 0.09), recovery room ($31 Ϯ 40 vs. $65 Ϯ 33; p ϭ 0.002) and pulmonary function testing costs ($0 Ϯ 0 vs. $34 Ϯ 103; p ϭ 0.045) than patients who received fentanyl. Anesthesia costs were higher among patients who received remifentanil ($476 Ϯ 102 vs. $416 Ϯ 130; p ϭ 0.06). Medical and surgical supplies, OR, ICU, cardiac catheterization, laboratory, respiratory therapy, pharmacy, radiology and transfusion costs were similar between the 2 groups (p Ͼ 0.05). The total cost was $15,272 Ϯ 5,556 and $15,616 Ϯ 4,169 in the remifentanil and fentanyl groups, respectively (p ϭ 0.81). CON-CLUSION: Remifentanil, when used in off-pump bypass surgery, increases the likelihood of extubation in the OR. However, LOS and total hospital costs remain unchanged. Solvay Pharmaceuticals, Hannover, Germany BACKGROUND: Atrial Fibrillation (AF) is the most frequent type of arrhythmia. Termination of acute AF is generally undertaken in a hospital setting. Available drugs for termination of acute AF have severe side effects and complicated dose regimens. There is a need for new drugs with a high conversion rate, favourable safety profile and easier dosing. OBJECTIVES: To describe the characteristics and hospital treatment patterns of patients with AF. To investigate the requirements for an improved cost-effective anti-arrhythmic therapy. METHODS: A database was used containing aggregated and anonymised diagnostic information, hospital experience (e.g., length of stay), and demographic data for over 80 million inpatient episodes in the UK over ten years. The database contains 28,524 hospital admissions of patients (65 and over) with a diagnosis of AF during 1999/2000. 53.3% are female, with mean length of stay (LOS) 6.1 days; 46.7% are male with LOS 4.3 days. Controlling for age, the gender LOS difference is significant (p Ͻ 0.01). RE-SULTS: Comorbid Conditions. 17.5% of AF patients also had a diagnosis of chronic ischaemic heart disease (IHD), a further 7.5% had myocardial ischaemia, and 19.5%, congestive heart failure. Furthermore, 24.2% of CHF patients and 16.9% of all angina patients also had clinically significant AF. Cardioversion. Cardioversion (defibrillation) is used when pharmacological therapy fails to terminate acute AF. However, significant numbers (35%) of cardioversion procedures were undertaken on an elective day case basis. We are currently investigating and will report on the resource consequences in acute AF. CONCLUSIONS: There is a clear unmet medical need for improved anti-arrhythmic drugs. Using the dataset, we identify two potentially cost-effective possibilities for improved anti-arrhythmic treatment: an agent which can simultaneously demonstrate effectiveness in associated cardiovascular conditions such as IHD or CHF; or an agent reducing the need for cardioversion in acute AF. Prophylactic infusion of factor VIII has been shown to markedly reduce arthropathy in patients with severe hemophilia A. OBJECTIVE: The purpose of this model is to investigate the cost-effectiveness of prophylactic infusion of factor VIII relative to on-demand infusion therapy in patients with severe hemophilia A. METHODS: Two hypothetical cohorts were modeled; one cohort receiving prophylactic and the other on-demand infusions. Factor VIII infusion therapy begins at age 1 and continues unchanged over a patient's lifetime. A recursive Markov model is used to estimate the expected costs and QALYs associated with each cohort. Costs and QALYs are calculated using backward induction in 5-year intervals incorporating the DEALE method. Data inputs are estimated from published literature. The analysis is completed from a societal perspective, uses a 3% discount rate, with costs in year 2000 U.S. dollars, and has a time horizon of 50 years. RESULTS: According to the model, patients re-
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USING UK OBSERVATIONAL DATA TO IDENTIFY POSSIBILITIES FOR THE COST-EFFECTIVE IMPROVEMENT OF THE TREATMENT OF ATRIAL FIBRILLATION
